Handling conflicts of interest at the EMA: impossible to satisfy everyone
This article was originally published in SRA
The European Medicines Agency is reviewing its policy on conflicts of interest for the scientific experts involved in activities at the agency. Neena Brizmohun discusses some of the changes the agency might need to consider.
You may also be interested in...
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
New medicines under evaluation at the European Medicines Agency.
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.